Please wait while the formulary information is being retrieved.
OJJAARA (momelotinib dihydrochloride)
- myelofibrosis
100 mg tablet
- 1 tablet (100 mg) by oral route once daily
150 mg tablet
- 1 tablet (150 mg) by oral route once daily
200 mg tablet
- 1 tablet (200 mg) by oral route once daily
Default screening record
- 1 tablet (100 mg) by oral route once daily
- 1 tablet (150 mg) by oral route once daily
- 2 tablets (200 mg) by oral route once daily
- 1 tablet (200 mg) by oral route once daily
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactation
Contraindicated
- Abnormal hepatic function tests
- Atherosclerotic cardiovascular disease
- Child-pugh class C hepatic impairment
- Disease of liver
- Infection
- Malignancy
- Malignant lymphoma
- Neutropenic disorder
- Thrombocytopenic disorder
- Thrombotic disorder
- Tobacco smoker
- Viral hepatitis B
Severe
Moderate
- None
OJJAARA (momelotinib dihydrochloride)
- myelofibrosis
- Bacterial infection
- Hemorrhage
- Thrombocytopenic disorder
- Abnormal hepatic function tests
- Diarrhea
- Dizziness
- Fatigue
- Hyperbilirubinemia
- Hypotension
- Nausea
More Frequent
Severe
Less Severe
- Cardiac arrhythmia
- Fungal infection
- Pneumonia
- Reactivation of hepatitis B
- Thrombotic disorder
- Viral infection
- Acute abdominal pain
- Back pain
- Cough
- Edema
- Fever
- Neutropenic disorder
- Pain in extremities
- Paresthesia
- Pruritus of skin
- Skin rash
- Syncope
- Thiamine deficiency
- Urinary tract infection
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute kidney injury
Less Severe
- Blurred vision
- Flushing
- Neuralgia
- Peripheral motor neuropathy
- Peripheral neuropathy
- Polyneuropathy
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Momelotinib
No pediatric safety and efficacy established.
- 1 Day – 18 Years
- No pediatric safety and efficacy established.
Momelotinib
- Severity Level:
2
- Additional Notes: Insuff human data avail; animal data suggests dev tox
Contraindicated
Momelotinib
Mfr recommends avoid breastfeeding during tx and for 1 week after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfr recommends avoid breastfeeding during tx and for 1 week after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Myelofibrosis | |
| D47.4 | Osteomyelofibrosis |
| D75.81 | Myelofibrosis |
| 0-9 | A-Z |
|---|---|
| D47.4 | Osteomyelofibrosis |
| D75.81 | Myelofibrosis |
Formulary Reference Tool